Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk

被引:36
|
作者
Kim, Jin You [1 ,2 ]
Kim, Jin Joo [1 ]
Hwangbo, Lee [1 ]
Lee, Ji Won [1 ]
Lee, Nam Kyung [1 ]
Nam, Kyung Jin [3 ]
Choo, Ki Seok [3 ]
Kang, Taewoo [4 ]
Park, Heeseung [4 ]
Son, Yohan [5 ]
Grimm, Robert [6 ]
机构
[1] Pusan Natl Univ Hosp, Med Res Inst, Dept Radiol, Busan, South Korea
[2] Pusan Natl Univ, Dept Radiol, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea
[3] Pusan Natl Univ, Dept Radiol, Yangsan Hosp, Yangsan, South Korea
[4] Pusan Natl Univ Hosp, Busan Canc Ctr, Busan, South Korea
[5] Siemens Healthineers Ltd, Seoul, South Korea
[6] Siemens Healthcare GmbH, Erlangen, Germany
关键词
Diffusion magnetic resonance imaging; Breast neoplasms; Oncotype DX; Recurrence; Biomarkers; ADJUVANT SYSTEMIC THERAPY; ONCOTYPE-DX; AMERICAN-SOCIETY; EARLY-STAGE; TUMOR HETEROGENEITY; GENE-EXPRESSION; COEFFICIENT; CHEMOTHERAPY; WOMEN; SURVIVAL;
D O I
10.1007/s00330-019-06383-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay. Methods This retrospective study was conducted on 105 women (median age, 48 years) with ER-positive, HER2-negative, node-negative breast cancer who underwent the Oncotype DX test and preoperative diffusion-weighted imaging (DWI). Histogram analysis of pixel-based ADC data of whole tumors was performed, and various ADC histogram parameters (mean, 5th, 25th, 50th, 75th, and 95th percentiles of ADCs) were extracted. The ADC difference value (defined as the difference between the 5th and 95th percentiles of ADCs) was calculated to assess intratumoral heterogeneity. Associations between quantitative ADC metrics and the recurrence risk, stratified using the Oncotype DX recurrence score (RS), were evaluated. Results Whole-lesion histogram analysis showed that the ADC difference value was different between the low-risk recurrence (RS < 18) and the non-low-risk recurrence (RS >= 18; intermediate to high risk of recurrence) groups (0.600 x 10(-3) mm(2)/s vs. 0.746 x 10(-3) mm(2)/s, p < 0.001). Multivariate regression analysis demonstrated that a lower ADC difference value (< 0.559 x 10(-3) mm(2)/s; odds ratio [OR] = 5.998; p = 0.007) and a small tumor size (<= 2 cm; OR = 3.866; p = 0.012) were associated with a low risk of recurrence after adjusting for clinicopathological factors. Conclusions The ADC difference value derived from whole-lesion histogram analysis might serve as a quantitative DWI biomarker of the recurrence risk in women with ER-positive, HER2-negative, node-negative invasive breast cancer.
引用
收藏
页码:66 / 76
页数:11
相关论文
共 50 条
  • [31] Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer
    Nguyen, Thi Truc Anh
    Postlewait, Lauren M.
    Zhang, Chao
    Meisel, Jane L.
    O'Regan, Ruth
    Badve, Sunil
    Kalinsky, Kevin
    Li, Xiaoxian
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (03) : 509 - 516
  • [32] A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
    Masahiro Takada
    Shigeru Imoto
    Takanori Ishida
    Yoshinori Ito
    Hiroji Iwata
    Norikazu Masuda
    Hirofumi Mukai
    Shigehira Saji
    Takafumi Ikeda
    Hironori Haga
    Toshiaki Saeki
    Kenjiro Aogi
    Tomoharu Sugie
    Takayuki Ueno
    Shinji Ohno
    Hiroshi Ishiguro
    Chizuko Kanbayashi
    Takeshi Miyamoto
    Yasuhiro Hagiwara
    Masakazu Toi
    Breast Cancer Research and Treatment, 2023, 202 : 485 - 496
  • [33] A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
    Takada, Masahiro
    Imoto, Shigeru
    Ishida, Takanori
    Ito, Yoshinori
    Iwata, Hiroji
    Masuda, Norikazu
    Mukai, Hirofumi
    Saji, Shigehira
    Ikeda, Takafumi
    Haga, Hironori
    Saeki, Toshiaki
    Aogi, Kenjiro
    Sugie, Tomoharu
    Ueno, Takayuki
    Ohno, Shinji
    Ishiguro, Hiroshi
    Kanbayashi, Chizuko
    Miyamoto, Takeshi
    Hagiwara, Yasuhiro
    Toi, Masakazu
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (03) : 485 - 496
  • [34] Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer
    Gong, Chang
    Tan, Weige
    Chen, Kai
    You, Na
    Zhu, Shan
    Liang, Gehao
    Xie, Xinhua
    Li, Qian
    Zeng, Yunjie
    Ouyang, Nengtai
    Li, Zhihua
    Zeng, Musheng
    Zhuang, ShiMei
    Lau, Wan-Yee
    Liu, Qiang
    Yin, Dong
    Wang, Xueqin
    Su, Fengxi
    Song, Erwei
    EBIOMEDICINE, 2016, 11 : 199 - 209
  • [35] Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
    Ogiya, Akiko
    Yamazaki, Kieko
    Horii, Rie
    Shien, Tadahiko
    Horimoto, Yoshiya
    Masuda, Norikazu
    Inao, Touko
    Hosoda, Mitsuchika
    Ishida, Naoko
    Osako, Tomofumi
    Takahashi, Masato
    Endo, Yumi
    Miyoshi, Yuichiro
    Yasojima, Hiroyuki
    Tomioka, Nobumoto
    Yamashita, Hiroko
    BREAST CANCER, 2017, 24 (03) : 473 - 482
  • [36] Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer
    Chae, Sun Young
    Park, Seol Hoon
    Lee, Hyo Sang
    Ahn, Jin-Hee
    Kim, Sung-Bae
    Jung, Kyung Hae
    Kim, Jeong Eun
    Ahn, Sei Hyun
    Son, Byung Ho
    Lee, Jong Won
    Ko, Beom Seok
    Kim, Hee Jeong
    Gong, Gyungyub
    Oh, Jungsu S.
    Park, Seo Young
    Moon, Dae Hyuk
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [37] Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer
    Han, Yunan
    Miao, Zhi-Feng
    Lian, Min
    Peterson, Lindsay L.
    Colditz, Graham A.
    Liu, Ying
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (03) : 915 - 925
  • [38] Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer
    Chae, Eun Young
    Moon, Woo Kyung
    Kim, Hak Hee
    Kim, Won Hwa
    Cha, Joo Hee
    Shin, Hee Jung
    Choi, Woo Jung
    Han, Wonshik
    Noh, Dong-Young
    Lee, Sae Byul
    Ahn, Sei Hyun
    PLOS ONE, 2016, 11 (06):
  • [39] Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis
    Babacan, Taner
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Kertmen, Neyran
    Suner, Ali
    Sarici, Furkan
    Akin, Serkan
    Ates, Ozturk
    Karakas, Yusuf
    Aslan, Alma
    Diker, Omer
    Altundag, Kadri
    JOURNAL OF BUON, 2015, 20 (02): : 479 - 486
  • [40] Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients
    Wu Jiayi
    Fang Yan
    Lin Lin
    Fei Xiaochun
    Gao Weiqi
    Zhu Siji
    Zong Yu
    Chen Xiaosong
    Huang Ou
    He Jianrong
    Zhu Li
    Chen Weiguo
    Li Yafen
    Shen Kunwei
    ONCOTARGET, 2017, 8 (24) : 38706 - 38716